about
The Possible Future Roles for iPSC-Derived Therapy for Autoimmune DiseasesBioengineering and Stem Cell Technology in the Treatment of Congenital Heart DiseasePotential Role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular SurfaceMyogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement TherapyThe Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell TransplantationHelios expression coordinates the development of a subset of striatopallidal medium spiny neuronsmRNA transfection of mouse and human neural stem cell cultures.Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration.iPS Cells for Modelling and Treatment of Retinal DiseasesCyclin A1 is essential for setting the pluripotent state and reducing tumorigenicity of induced pluripotent stem cells.Long live the stem cell: the use of stem cells isolated from post mortem tissues for translational strategies.The State of Play with iPSCs and Spinal Cord Injury Models.Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1.The ETS-related factor TEL is regulated by angiogenic growth factor VEGF in HUVE-cells.Bioengineered Bruch's-like extracellular matrix promotes retinal pigment epithelial differentiation.Plant hormones increase efficiency of reprogramming mouse somatic cells to induced pluripotent stem cells and reduce tumorigenicity.Effects of the Post-Spinal Cord Injury Microenvironment on the Differentiation Capacity of Human Neural Stem Cells Derived from Induced Pluripotent Stem Cells.Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotencyiPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?Global Proteomic and Methylome Analysis in Human Induced Pluripotent Stem Cells Reveals Overexpression of a Human TLR3 Affecting Proper Innate Immune Response SignalingAnalysis of the TEL protein during tumour angiogenesisPhytoestrogens reduce bone loss and bone resorption in oophorectomized ratsAssessment of vascularity in breast carcinoma by computer-assisted video analysis (CAVA) and its association with axillary lymph node statusHigh density of small vessels expressing the tyrosine kinase receptor KDR in primary invasive breast carcinoma correlates with axillary lymph node metastasesThe cell cycle and pluripotency: Is there a direct link?Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis
P50
Q26799472-B7A7999F-2716-4002-871F-02FABCFFF292Q26799556-97C44F5B-935B-479A-919C-831918009C82Q26799621-55E90CBE-427D-45E5-8F94-71684F91BAB3Q26799633-EE048E39-778C-4E79-8170-9989B4EF0FE2Q28973616-852DED03-D1E1-4A85-9F57-E5C5FE965D85Q33588405-92F8385F-30B4-4B39-886D-612A6E4369BAQ35080495-6FBBEDBD-042C-4CF4-833F-327CFAC2E7D7Q35608700-623756DE-DD0E-4BAF-8A6B-BFD8CFF4BC54Q35750572-B0C12561-E4F2-401F-AF18-E8719485F5E2Q36296981-A37EB288-8EE4-4C8C-A097-4DCC4F6E3403Q38258619-2F08779C-08FB-4938-8D4D-802A8BB26414Q38559610-74916697-DF73-4D03-A245-CD2C017583C9Q39691123-5307328C-D2DA-44C0-9E30-D5516F00419BQ40979962-ADC84F9F-9AC3-4062-A64B-3D58CF68D055Q41682241-9B972BFC-DD90-495F-A916-2D836E7B0E6CQ41889376-9DBAC571-0CC1-4724-82CD-AE2F0831658EQ50244515-4159DA30-D491-4B2D-A271-32B2B63E67BFQ57562675-BFDDF026-B01D-4BC3-B7F4-B3FAC1886BC0Q64089132-922AC13C-AF81-4443-B361-5CA7EB810288Q64236762-2A4C4DE7-1E45-487D-907F-9BBD0059F223Q73397042-4118FEA2-8ECE-4788-A39E-13278B3899FFQ73648920-860AE2D8-BC1C-4D96-8F64-C5CEE53D3C27Q74288154-E0232386-B023-4D6F-BBC6-3E6FDAFD3058Q79097335-AA5CFB66-FCCD-4BB5-8288-19C0EBCCF5C5Q84484611-A0B97E0A-FA13-4467-905D-C1E5BF5C8B30Q96128943-33591AC5-7EA0-4FEF-B706-94C115AC5919
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael J Edel
@ast
Michael J Edel
@en
Michael J Edel
@es
Michael J Edel
@nl
type
label
Michael J Edel
@ast
Michael J Edel
@en
Michael J Edel
@es
Michael J Edel
@nl
prefLabel
Michael J Edel
@ast
Michael J Edel
@en
Michael J Edel
@es
Michael J Edel
@nl
P108
P106
P108
P214
1145424144486790358
P31
P496
0000-0002-5619-8680
P7859
viaf-1145424144486790358